anti-CD3 + anti-CD20

A combination therapy consisting of two monoclonal antibodies: one targeting **CD3** (a T-cell surface protein) and the other targeting **CD20** (a B-cell surface protein). This combination can refer to either simultaneous use of individual anti-CD3 and anti-CD20 monoclonal antibodies or to anti-CD3/CD20 bispecific antibodies, which simultaneously bind CD3 on T cells and CD20 on B cells. - The canonical instance of this combination therapy in clinical and preclinical literature includes: - **Separate administration of anti-CD3 and anti-CD20 antibodies** (e.g., in type 1 diabetes models, oral anti-CD3 with intravenous anti-CD20) to synergistically modulate immune tolerance primarily by expanding regulatory T cells and inducing regulatory dendritic cells, enhancing prevention or reversal of autoimmunity[1]. - **Bispecific anti-CD3/CD20 antibodies** (e.g., mosunetuzumab, glofitamab, odronextamab), which are engineered antibodies with dual specificity; these physically crosslink CD3 on T cells to CD20 on B cells, facilitating T cell–mediated cytotoxicity and selective B cell depletion[5][6][9]. - The mechanism of action for both approaches involves direct B cell depletion through cytotoxicity and immunomodulation of T cells to promote immune tolerance or anti-tumor activity. - Principal indications studied include **B-cell malignancies** (lymphoma, leukemia), and **autoimmune diseases** (e.g., type 1 diabetes)[1][5].

Other names

anti-CD3 + anti-CD20 combinationanti-CD20 + anti-CD3 combination